A biological guide to glycosaminoglycans: current perspectives and pending questions
The FEBS Journal · 2024
DOI: 10.1111/febs.17107 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FEBS Journal, 2024. Verfasst von Sylvie Ricard-Blum und 12 weiteren Autor:innen. Beteiligte Einrichtung: Univ Lyon 1, ICBMS, UMR 5246 University Lyon 1 - CNRS, Villeurbanne cedex, France. Hauptthemen laut MEDLINE: Glycosaminoglycans. Die Arbeit wurde bisher 132-mal zitiert (Crossref) und nennt 274 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Mammalian glycosaminoglycans (GAGs), except hyaluronan (HA), are sulfated polysaccharides that are covalently attached to core proteins to form proteoglycans (PGs). This article summarizes key biological findings for the most widespread GAGs, namely HA, chondroitin sulfate/dermatan sulfate (CS/DS), keratan sulfate (KS), and heparan sulfate (HS). It focuses on the major processes that remain to be deciphered to get a comprehensive view of the mechanisms mediating GAG biological functions. They include the regulation of GAG biosynthesis and postsynthetic modifications in heparin (HP) and HS, the composition, heterogeneity, and function of the tetrasaccharide linkage region and its role in disease, the functional characterization of the new PGs recently identified by glycoproteomics, the selectivity of interactions mediated by GAG chains, the display of GAG chains and PGs at the cell surface and their impact on the availability and activity of soluble ligands, and on their move through the glycocalyx layer to reach their receptors, the human GAG profile in health and disease, the roles of GAGs and particular PGs (syndecans, decorin, and biglycan) involved in cancer, inflammation, and fibrosis, the possible use of GAGs and PGs as disease biomarkers, and the design of inhibitors targeting GAG biosynthetic enzymes and GAG–protein interactions to develop novel therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Univ Lyon 1, ICBMS, UMR 5246 University Lyon 1 - CNRS, Villeurbanne cedex, France.
- Univ. Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France.
- Institute of Pharmacology and Toxicology, Goethe University, Frankfurt, Germany.
- Department of Gynecology and Obstetrics, Münster University Hospital, Germany.
- University of Insubria, Varese, Italy.
- Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden.
ORCID-Profile: Sylvie Ricard-Blum, Celso A Reis, Nikos K Karamanos, Dragana Nikitovic
Zitieren
APA
Ricard-Blum, S., Vivès, R. R., Schaefer, L., Götte, M., Merline, R., Passi, A., Heldin, P., Magalhães, A., Reis, C. A., Skandalis, S. S., Karamanos, N. K., Perez, S., & Nikitovic, D. (2024). A biological guide to glycosaminoglycans: current perspectives and pending questions. The FEBS Journal. https://doi.org/10.1111/febs.17107
Vancouver
Ricard-Blum S, Vivès RR, Schaefer L, Götte M, Merline R, Passi A, et al. A biological guide to glycosaminoglycans: current perspectives and pending questions. The FEBS Journal. 2024. doi:10.1111/febs.17107
BibTeX
@article{RicardBlum2024,
author = {Ricard-Blum, Sylvie and Vivès, Romain R and Schaefer, Liliana and Götte, Martin and Merline, Rosetta and Passi, Alberto and Heldin, Paraskevi and Magalhães, Ana and Reis, Celso A and Skandalis, Spyros S and Karamanos, Nikos K and Perez, Serge and Nikitovic, Dragana},
title = {A biological guide to glycosaminoglycans: current perspectives and pending questions},
journal = {The FEBS Journal},
year = {2024},
doi = {10.1111/febs.17107}
}
EUVIMED